Biomarker guided PARP inhibitor maintenance improves outcomes in ovarian cancer meta analysis of phase 3 trials

Immune checkpoint inhibitors show setting specific benefit in ovarian cancer meta analysis of 17 randomised trials

Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC

Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Bladder cancer updates from the first half of 2026

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results

The impact of disease burden: Understanding patient priorities in aRCC

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer